This Week in Science

What happens when an everyday industrial chemical meets a tropical river? In this iScience study, bisphenol A (BPA) was found at all locations along Thailand’s Chao Phraya River, with levels increasing downstream. Researchers also link BPA persistence to dissolved oxygen—so river “health” may matter for chemical behavior too. Explore the findings here: https://doi.org/10.1016/j.isci.2026.117460

Why would the same pregnancy immune trigger affect sons more than daughters? In a mouse model, researchers observed that a subset of male embryos rapidly develop developmental abnormalities after maternal immune activation—linked to a shift toward a proinflammatory maternal-fetal interface. Interleukin-6 appears to be required for these effects. Learn what happens in the placenta and amniotic fluid here: https://doi.org/10.1126/sciadv.aeg0779

Could the “side” of radiotherapy influence heart risk later on? In a nationwide cohort of 23,305 women treated for breast cancer, left-sided RT showed a higher ischemic heart disease risk—but the effect wasn’t uniform. It was most evident for patients with 3 baseline cardiovascular risk factors. Explore the details here: https://doi.org/10.1001/jamanetworkopen.2026.31356

RSV can hit especially hard in newborns, young children, older adults, and people with weakened immune systems. This open-access iScience study looks at whether a GMP-manufactured recombinant BCG vaccine carrying an RSV nucleoprotein stays stable and continues to meet quality standards. It also reports safety and protection signals in mice. https://doi.org/10.1016/j.isci.2026.117131

Imagine a digital laboratory where you can try interventions on a virtual cell and see how outcomes unfold over time. This open-access paper proposes a “virtual cell world model” that’s built to simulate evolving cellular states and generate coherent molecular and structural results—not just single-step predictions. Curious how AI could help navigate cell biology more systematically?

https://doi.org/10.1016/j.cell.2026.08.042

What if one framework could connect the different “stories” written into a tumor’s DNA? This Nature paper identifies integrated mutational footprints (IMFs) that capture key DNA-damage and repair processes in prostate cancer genomes, including links to replication stress and androgen-receptor–mediated mutagenesis. The study also explores how these signatures relate to metastasis timing and predicted drug sensitivity.

Learn more: https://doi.org/10.1038/s41586-026-10468-w

What happens to someone who misses an HIV care visit—do they feel able to come back? This open-access analysis from Zambia suggests that improving the “caring” experience from healthcare workers can boost return after interruptions and help people stay engaged once they return. It’s a hopeful, practical look at reengagement, built from real clinic data. Explore the study: https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1005052&type=printable

What if some of California’s biggest winter rainstorms start thousands of miles away? This study connects record-breaking precipitation in 2016–2017 and 2022–2023 to early-winter warming over the Tibetan Plateau, even during La Niña years when California is often expected to be drier. By improving how the model “sees” Tibetan Plateau temperatures, the researchers reproduce a large fraction of the observed extreme rainfall.

Learn more here: https://doi.org/10.1126/sciadv.aeg3577

After prostate cancer, it’s not just whether you eat “healthy”—it’s what kind of fat you’re getting. This open-access study looked at diet after diagnosis and found saturated/animal fats were tied to higher overall death risk, while plant-based fats and monounsaturated fats were linked to better survival. Curious what this could mean for everyday choices?

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2853518/zhang_2026

Where are bladder cancer clinical trials located—and who’s left out? This study of ClinicalTrials.gov data finds that most US counties (77%) have no bladder cancer trial sites, and that trial availability clusters in areas with higher incidence and lower social vulnerability. It also explores how mortality and trial sponsor/size relate to location.

https://doi.org/10.1001/jamanetworkopen.2026.32012